{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-065119","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.656852+00:00","generated_at":"2026-06-01T08:36:52.989679+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Collegium appoints Michael Heffernan interim CEO with base salary $291,666; Ciaffoni separation agreed","bullets":["Michael Heffernan appointed Interim President and CEO effective May 24, 2024; annual base salary $291,666 (one-third of prior CEO).","Heffernan's employment is at-will; Board may terminate at any time or extend by mutual agreement.","Separation and Release Agreement with departing CEO Joseph Ciaffoni grants severance per employment agreement for termination without cause."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-065119","json":"https://secwatch.observer/filing/0001104659-24-065119.json","markdown":"https://secwatch.observer/filing/0001104659-24-065119.md","text":"https://secwatch.observer/filing/0001104659-24-065119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924065119/0001104659-24-065119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924065119/tm2415470d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:36:52.989679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ef891ba2b","claim":"Michael Heffernan was appointed as Interim President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"On May 24, 2024, Collegium Pharmaceutical, Inc. (the “Company”) entered into a letter agreement (the “Letter Agreement”) with Michael Heffernan in connection with Mr. Heffernan’s appointment as Interim President and Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924065119/0001104659-24-065119-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f91689985a","claim":"Joseph Ciaffoni departed as Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"Also on May 24, 2024, the Company entered into a Separation and Release Agreement with Mr. Ciaffoni (the “Separation Agreement”) in connection with his previously announced departure from the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465924065119/0001104659-24-065119-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}